U

UroGen Pharma, Inc

Develops RTGel-based drug delivery for uro-oncology

Territory Business Manager - Rare Disease

Field SalesPosted on Nov 10
Full-timeRemote in USA$165k - $175k /yr

About the Job

Requirements

  • A bachelor's degree in a related field is required.
  • At least 4 years of pharmaceutical, biotech, or medical device industry experience is required.
  • At least 3 years of sales experience is required.
  • The role requires travel 80% within the assigned territory and 20% for overnight stays and/or weekend events as needed.
  • A valid driver's license is required.

Responsibilities

  • Conduct direct customer-facing interactions and execute brand and sales strategy to demonstrate clinical product value and educate customers on appropriate utilization.
  • Use knowledge of local market trends, institutions, and key customers to maximize territory-level results.
  • Collaborate with matrix team members to establish and improve territory performance.
  • Partner effectively with internal and external stakeholders.
  • Use internal resources and data analysis to create territory business plans that drive results.
  • Identify opportunities to build organizational efficiency and improve processes to positively impact the business.
  • Understand opportunities unique to the assigned geography.

Desired Qualifications

  • At least 2 years of hospital or large-account experience.
  • At least 2 years of experience in uro-oncology, oncology, rare disease, or medical devices.
  • Experience with Buy & Bill products.
  • Experience in the urological rare disease space.

About the Company

UroGen Pharma, Inc

Develops RTGel-based drug delivery for uro-oncology

UroGen Pharma develops RTGel-based drug-delivery therapies for urothelial and specialty cancers, commercializing products like Jelmyto and ZUSDURI and advancing a pipeline that includes UGN-102, UGN-103, UGN-104, and UGN-301. Its RTGel platform is liquid at cool temperatures and gels at body temperature, allowing chemotherapy to stay at the treatment site longer for local, sustained exposure. The company differentiates itself by delivering established chemotherapy directly to the disease site to reduce systemic exposure and by building a multi-product portfolio focused on urothelial cancers. Its goal is to improve local treatment outcomes and grow a diversified, globally commercial portfolio through ongoing clinical development and partnerships.

Company size
201-500
Company stage
IPO
Headquarters
Princeton, NJ
Founded
2004

Recently Posted Jobs

Explore more opportunities at UroGen Pharma, Inc

See more jobs